HLA-A*02:01 is frequently targeted in TCR-based therapies (e.g., TCR-T cells, CAR-Tregs) due to its role in presenting tumor-associated antigens such as NY-ESO-1, MART-1, and MAGE-A3. This evidence concerns the gene MAGEA3 and neoplasm.